Research Article
Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Table 4
Clinical response for the first-line treatment stratum.
| | Response to treatment | Global population | Locally advanced
(%) | Metastatic
(%) | Total
(%) |
| | Complete response (CR) | 2 (8.7) | — | 2 (3.08) | | Partial response (PR) | 7 (30.4) | 3 (7.14) | 10 (15.4) | | Stable disease (SD) | 5 (21.7) | 11 (26.2) | 16 (24.6) | | Progressive disease (PD) | 4 (17.4) | 6 (14.3) | 10 (15.4) | | No objective evaluation (NE) | 5 (21.7) | 19 (45.2) | 24 (36.9) | | Objective response (OR) | 9 (39.1) | 3 (7.14) | 12 (18.5) | | 95% confidence interval (CI) | 26.0-73.9 | 3.2-37.8 | 15.5-7.7 | | Disease control (DC) | 14 (60.9) | 14 (33.3) | 28 (43.1) | | 95% confidence interval (CI) | 52.3-93.5 | 45.7-88.1 | 58.4-9.0 | | Total | 23 (100) | 42 (100) | 65 (100) |
|
|
Included patients who had either early death or symptomatic deterioration but no objective evaluation. |
